Abstract

BackgroundThe utility of generic health-related quality of life (HRQoL) questionnaires in patients with systemic lupus erythematosus (SLE) is uncertain. We compared the performance of generic (SF36) and specific (SLEQOL) HRQoL surveys by examining their associations with the Global Rating of Change (GRC) and SLE clinical indicators.MethodsThe study included SLE patients who attended a single-center rheumatology clinic between 2013 and 2017. Patients completed both specific (SLEQOL) and generic (SF36) surveys and rated their GRC compared to the previous visit using a 7-point Likert scale on the same day of routine visits. Based on GRC scores, patients’ change in HRQoL was categorized as “no change,” “deterioration,” or “improvement.” Disease activity (SLEDAI-2K), flare, and lupus low disease activity state (LLDAS) were assessed at each visit, and organ damage (SDI) was determined annually. Pairwise correlations between SLEQOL and SF36 components were examined, and associations between GRC status and SLE disease indicators were compared using generalized estimating equations (GEE).ResultsThree hundred thirty-seven patients with 2062 visits were included in the analysis. SLEQOL correlated significantly with SF36. Patients reported improvements in HRQoL in 58%, deterioration in 15%, and “no change” in 27% of all visits. Compared to the “no change” group, mean SF36 and SLEQOL scores were significantly lower in the deterioration group and higher in the improvement group. The magnitude of changes observed with SLEQOL and SF36 in the deterioration and improvement groups was similar. Patients in LLDAS had significantly higher mean scores in both SLEQOL and SF36. In contrast, patients with active disease, especially those with cutaneous, renal, central nervous system, and musculoskeletal activity, had significantly lower SLEQOL and SF36. Flare and organ damage were also associated with lower SLEQOL and SF36-PCS (physical component) but not with SF36-MCS (mental component).ConclusionSLEQOL and SF36 similarly describe HRQoL in SLE. Both instruments demonstrated strong associations with GRC-based deterioration or improvement as well as SLE disease status. LLDAS was associated with improved HRQoL.

Highlights

  • The utility of generic health-related quality of life (HRQoL) questionnaires in patients with systemic lupus erythematosus (SLE) is uncertain

  • About 95% of patients were treated with glucocorticoids, with a Time-adjusted means (TAM) prednisolone dose across the period of observation of 5.8 ([3.7, 9.3] (0, 61)) mg/ day

  • The six patients who reported deterioration at every visit had the shortest study duration with a median (IQR) of 5.8 (5.5, 6.9) months; in contrast, patients who Associations of Global Rating of Change (GRC) categories with SLE Quality of Life (SLEQOL), 36-Item Short-Form Health Survey (SF36), and clinical indicators To determine whether patient-reported GRC correlated with changes in instrument-measured HRQoL, we examined the magnitude of mean changes in SLEQOL and SF36 scores in GRC categories

Read more

Summary

Introduction

The utility of generic health-related quality of life (HRQoL) questionnaires in patients with systemic lupus erythematosus (SLE) is uncertain. Due to a lack of effective therapy, patients suffer from inadequately controlled disease, and from treatment-associated complications [2, 3] All these factors contribute to significant increases in morbidity and mortality, and poor health-related quality of life (HRQoL) [1, 2], both of which are more pronounced in developing countries [4]. SLE-specific HRQoL instruments have been developed and validated in several countries These include the SLE Quality of Life (SLEQOL) [7,8,9], Lupus Quality of Life (LupusQoL) [10,11,12], Lupus Patient-Reported Outcome (LupusPRO) [13,14,15,16,17], SLE Symptom Checklist (SSC) [18, 19], and SLE Quality of Life Questionnaire (L-QoL) [20, 21]. Recommendations for HRQoL instrument used in research and clinical practice in SLE lack evidence that is based on a robust comparison between generic and disease-specific measures

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call